Viking Therapeutics Bets Big on Obesity Breakthroughs

Viking Therapeutics ((VKTX)) has held its Q4 earnings call. Read on for the main highlights of the call.

Viking Therapeutics’ latest earnings call balanced ambitious clinical momentum with mounting financial strain. Management highlighted standout weight‑loss data, rapid Phase III enrollment and advancing manufacturing and commercial plans, arguing these milestones outweigh sharply rising R&D costs, widening losses and an evolving competitive landscape in obesity drugs.

Subcutaneous VK2735 Delivers Double‑Digit Weight Loss

Phase II VENTURE data for subcutaneous VK2735 showed statistically significant weight loss of up to 14.7% after 13 weekly doses, reinforcing the candidate’s competitive profile in obesity. Earlier Phase I cohorts delivered around 8% weight loss after just four weeks, with management describing safety and tolerability as encouraging and adverse events mostly mild or moderate.

Oral VK2735 Shows Strong Phase II Efficacy

In the VENTURE‑Oral study, once‑daily oral VK2735 achieved up to 12.2% mean weight loss at 13 weeks, with statistical separation from placebo emerging as early as week one at doses above 15 mg. Up to 80% of treated subjects hit at least 10% weight loss versus just 5% on placebo, positioning the oral pill as a serious contender in the emerging oral obesity segment.

Phase III VANQUISH Program Scales Rapidly

Viking has launched the VANQUISH Phase III program, splitting development between VANQUISH‑1 in obesity and VANQUISH‑2 in obesity with type 2 diabetes. VANQUISH‑1 is already fully enrolled ahead of schedule and has surpassed its roughly 4,500‑patient target, while VANQUISH‑2, targeting about 1,100 patients, is nearing enrollment completion.

Oral Candidate Poised for Phase III in 2026

Following positive oral Phase II results and an end‑of‑Phase II meeting with regulators, Viking plans to start a Phase III program for oral VK2735 in the third quarter of 2026. Management expects this program to be leaner than the injectable VANQUISH trials, potentially featuring shorter duration, fewer patients and reduced visit intensity to accelerate timelines and control costs.

Maintenance Dosing Study to Inform Real‑World Use

The company has fully enrolled a Phase I maintenance dosing study that finished enrollment in January 2026 and is designed to mirror longer‑term clinical practice. After 19 weeks of weekly dosing, participants transition to a range of regimens, including monthly, every‑other‑week and weekly injections, plus weekly and daily oral arms, with results due in the third quarter of 2026.

Commercial and Manufacturing Infrastructure Taking Shape

To prepare for potential commercialization, Viking signed a broad manufacturing and supply deal with CordenPharma to provide large‑scale active ingredient and fill‑finish services for both injectable and oral formats. The company also appointed Neil Aubuchon as chief commercial officer, signaling a pivot toward launch planning in what it views as a multibillion‑dollar obesity opportunity.

Pipeline Broadens With Amylin Agonist Program

Beyond VK2735, Viking is advancing an amylin receptor agonist as a complementary obesity mechanism, aiming to deepen its metabolic franchise. An investigational filing is expected this quarter, with first‑in‑human dosing likely in the second quarter of 2026 and initial Phase I data potentially arriving later in 2026.

Cash Runway Supports Near‑Term Catalysts

Viking ended 2025 with $706 million in cash, cash equivalents and short‑term investments, which management believes will fund the company through key clinical milestones. That runway is expected to cover the maintenance study readout, subcutaneous Phase III data and top‑line results from the planned oral Phase III program, even as development activity ramps further.

R&D Spending Surges on Late‑Stage Trials

R&D expenses rose sharply as programs moved into costly late‑stage studies, with fourth‑quarter R&D jumping to $153.5 million from $31.0 million a year earlier. For the full year, R&D climbed to $345.0 million from $101.6 million, reflecting Phase III trial execution, expanded manufacturing work, higher personnel costs and rising stock‑based compensation.

Net Loss Widens as Investment Intensifies

The company’s net loss swelled alongside that spending, with fourth‑quarter losses reaching $157.7 million, or $1.38 per share, compared with $35.4 million, or $0.32 per share, in the prior‑year quarter. Full‑year net loss expanded to $358.5 million, or $3.19 per share, versus $110.0 million, or $1.01 per share, underscoring the cost of Viking’s aggressive development push.

Cash Balance Declines Amid Heavy Investment

Viking’s cash and short‑term investments fell to $706 million at year‑end 2025 from $903 million a year earlier, a drop of about $197 million or roughly 21.8%. Management framed this decline as a deliberate investment in late‑stage trials and infrastructure meant to unlock substantial long‑term value if VK2735 and other pipeline assets succeed.

High Ongoing Cash Burn a Key Risk

Looking ahead, the finance team expects quarterly cash usage to run in the $60 million to $90 million range as Phase III programs and manufacturing build‑out continue. That burn rate underscores Viking’s reliance on its current balance and future capital access, a key consideration for investors watching dilution risk and market conditions.

Market Competition and Reimbursement Remain Wild Cards

Management acknowledged that the obesity market is evolving rapidly, with new oral peptides and deep‑pocketed entrants reshaping the landscape and raising strategic questions. The company sees potential in partnering and is closely watching payer expectations, noting that long‑term outcomes data could become important for reimbursement and market access.

Managing Tolerability and GI Side Effects

While the company emphasized an overall encouraging safety profile, gastrointestinal side effects were observed, particularly early in treatment, and remain under close watch. Viking suggested that dose titration and optimized regimens from the maintenance study could help mitigate these events and improve long‑term adherence in real‑world use.

Busy 2026 Roadmap and Clinical Milestones

Executives outlined a packed 2026 agenda, including initiation of the oral VK2735 Phase III program and maintenance study results in the third quarter. They also plan to complete VANQUISH‑2 enrollment, roll out an auto‑injector in the first quarter, initiate first dosing for the amylin agonist in the second quarter and advance 78‑week VANQUISH trials across multiple weekly dose arms, all funded by the current cash base despite elevated R&D spend.

Viking’s earnings call painted a picture of a company leaning hard into the obesity opportunity, with data that could support both injectable and oral franchises. For investors, the appeal lies in the robust efficacy and advancing pipeline, weighed against heavy cash burn, intensifying competition and execution risk as the story moves decisively into late‑stage development.